235 results about "Colonic cancer" patented technology

Methods of identifying subjects at increased risk of cancer, based upon detection of biofilms and/or biofilm-associated microbes within a subject, are disclosed. Therapies designed to prevent formation and/or reduce the size of biofilms in a subject identified to be at increased risk of cancer based upon detection of biofilms and/or biofilm-associated microbes are disclosed. In particular embodiments, the invention provides for identification of a subject at elevated risk of developing or having colorectal cancer and/or a colorectal adenoma, based upon detection of a biofilm and/or biofilm-associated bacteria within the gastrointestinal tract of the subject (optionally, within a biopsy specimen and/or stool sample of such subject). Therapies involving administration of an antibiotic agent and/or a probiotic agent to a subject, to prevent or reduce biofilm formation within the gastrointestinal tract of the subject, optionally provided in combination with additional cancer therapy, are also disclosed.

A method of providing a prognosis of colorectal cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

This application describes methods and compositions for detecting and treating HLTF-associated neoplasia. Differential methylation of the HLTF nucleotide sequences has been observed in HLTF-associated neoplasia such as colon neoplasia.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

Differential gene expression associated with histopathologic features of colorectal disease can be performed with nucleic acid arrays. Such arrays can comprise a pool of polynucleotide sequences from colon tissues, and the detection of the overexpression or underexpression of polynucleotide sequences (or subsequences or complements thereof) from this pool can provide information relating to the detection, diagnosis, stage, classification, monitoring, prediction, prevention or treatment of colorectal disease.

The present invention relates to a method for diagnosing colon cancer by detecting a colon cancer specific antigen, defensin α6 from the blood of patient and a diagnostic kit for colon cancer comprising anti-defensin α6 antibody. The diagnostic kit for colon cancer of present invention comprises: a solid support such as 96-well plate for ELISA, nitrocellulose membrane, polyvinylidene fluoride membrane, microplate, glass substrate, polystyrene substrate, silicone substrate or metal plate, on which anti-defensin α6 antibody is immobilized; and, a means for detecting colon cancer specific antigen such as a primary antibody which specifically binds with an antigen conjugated with an antibody on a solid substrate and a secondary antibody-signal complex which specifically binds with the primary antibody. The diagnostic kit of the invention can diagnose colon cancer with the minute amount of patients' blood, which makes possible the easy and simple diagnosis of colon cancer.

Objective methods for detecting and diagnosing Colorectal and gastric carcinomas are described herein. In one embodiment, the diagnostic method involves the determining a expression level of colon or gastric cancer—associated gene that discriminate between colon or gastric cancer and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of colonic cancer and method of vaccinating a subject against colon or gastric cancer.

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Provided herein are methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway in a subject using an inhibitor of aldose reductase. Particularly, specific inhibitors may be small molecules such as fidarestat or siRNA. Also, methods of treating breast and prostate cancers or suppressing metastasis of colon cancer thereof using the siRNAs and aldose reductase inhibitors are provided.

A method for the early diagnosis of breast, lung, pancreatic and colon growths and cancers as well as conditions associated with donor and recipient organ transplants, both before and after transplantation to identify and allow treatment of possible transplanted organ rejection and other disease conditions related and unrelated to the transplantation, compares the gene expression patterns from a patient's peripheral blood monocytes-lymphocyte's gene system with either the similar gene expression patterns of a normal person, or with the similar gene expression patterns of a person known to have the condition being screened for. Differences between the patient's gene expression patterns for particular genes and the normal patterns indicates the presence of the condition with the number of differences indicating the probability of the condition. Similarities between the patient's gene expression patterns for those particular genes and the patterns of a person known to have the condition indicates the presence of the condition with the number of similarities indicating the probability of the condition. Portions of the method may be performed with the use of a microfluidic machine.

The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I:

wherein R¹, R², and R³ are defined herein.

The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

The present invention is concerned with a novel antigens associated with human tumors, including carcinomas of the colon or lung, as well as novel monoclonal antibodies which specifically bind to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antigens include 100 kDa glycoprotein that has a colorectal cancer membrane bound and a soluble form, has a UV absorbance peak at about 228 nm, an isoelectric point of about 3.5 to 4, a sialic acid content of about 20%, and does not substantially bind to an antibody specific for ACT. The antibodies find use both in methods such as the detection of malignant cells associated with tumors and in monitoring therapeutic treatment of humans with tumors.

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.

The invention discloses a composition with an effect of preventing and treating cancers. The composition is mainly prepared from the following Chinese herbal medicines in percentage by mass: 20 to 85 percent of airpotato yam rhizome and 15 to 80 percent of Chinese angelica. The Chinese medicinal composition has the effect of preventing and treating the cancers, can eliminate the limit that liver injury is easily induced by chemotherapeutic medicinal medicines, is suitable for treating various cancers such as liver cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, ovarian cancer, prostate cancer, esophagus cancer, pancreatic cancer, colon cancer, colorectal cancer, skin cancer, thyroid cancer, cervical carcinoma, leukemia and the like, can be used for preparing anti-cancer medicaments, realizes the application of the airpotato yam rhizome and Chinese angelica compositions to the preparation of medicaments for treating the cancers, develops the application range and the medicinal value of the airpotato yam rhizome and the Chinese angelica and makes creative contribution to the development of traditional Chinese medicine.

The invention provides application of METRNL protein as a protein molecule marker for detecting colon cancer and application of the METRNL protein in preparing a colon cancer diagnostic reagent or a kit. Immunohistochemistry is carried out on 30 pairs of human colon cancer tissues and para-carcinoma tissues through immunohistochemistry tests, and the result proves that the METRNL protein has differential expression in cancer tissues and para-carcinoma tissues of the human colon cancer. Therefore, whether a patient has the colon cancer can be detected according to the expression quantity of the METRNL protein in colon tissues.

The invention provides a preparation method of avenanthramide and a derivative thereof. The avenanthramide and the derivative thereof are synthesized and obtained by mainly utilizing an organic acid and aminobenzoic acid as major reactants. The method is high in yield, few in by-products and applicable to the industrialized production of the avenanthramide and the derivative thereof. The avenanthramide has multiple bioactivities of anti-oxidation, anti-anaphylaxis, anti-proliferation and itching relief, meanwhile, also has certain effects of treating coronary disease and colonic cancer, and is often used in products of a emulsion skincare article, an after-sun repairing article, a rhinitis spray, a skin itching relieving infantile product, an externally used cream for treating dermatitis and the like.